“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Sales Of Olainfarm In August Increase By 19% September 14, 2017 Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017 Mirati Therapeutics Reports Second Quarter 2017 Financial Results August 3, 2017
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017
